ClinicalTrials.gg
CompletedNCT06528821AI-ECG-TIMIUpdated Nov 18, 2026

AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS

An observational study in Acute Coronary Syndrome, STEMI and Coronary Occlusion, sponsored by Powerful Medical. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Powerful Medical · Observational

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
718
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Acute Coronary Syndrome with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Acute Coronary Syndrome · Austria.

Started
2024
with 2 others
Observational
8 of 34
2 open now
Registered
32nd of 34
by date

Among the 34 studies in Acute Coronary Syndrome with a site in Austria, this one is one of 3 that started in 2024, is one of 8 observational ones, and was the 32nd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

3 of the 34 studies in Acute Coronary Syndrome with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Acute Coronary Syndrome with a site in Austria, or all of them as a file.
02

Study summary

AI ECG TIMI is an investigator-initiated, international, and multicenter registry of acute coronary syndrome patients aimed to identify electrocardiographic findings detected by an AI model predicting coronary blood flow alteration. The aim of the study is to identify electrocardiographic findings detected by an automated artificial intelligence (AI) model that can predict coronary blood flow alteration as assessed by the TIMI grade flow at the very moment of the invasive coronary angiography in patients with acute coronary syndromes.

03

Conditions studied

  • Acute Coronary Syndrome
  • STEMI
  • Coronary Occlusion
  • Coronary Syndrome
  • NSTEMI
  • NSTEMI - Non-ST Segment Elevation MI

Keywords

  • Acute Coronary Syndrome
  • ECG
  • Artificial Intelligence
  • Occlusion Myocardial Infarction
  • Myocardial Infarction (MI)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults (18 or older) with acute coronary syndrome undergoing clinically indicated invasive coronary angiography, with a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute coronary syndromes undergoing invasive coronary angiography as clinically indicated.
  • Availability of a standard 12-lead performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access).
  • Age ≥18 years.

Exclusion criteria

Exclusion Criteria:

  • Individuals presenting for a non-emergent (elective) cardiac catheterization.
  • Individuals presenting with chronic coronary syndrome (CCS) or stable angina symptoms.
  • Individuals without symptoms suspicious for acute coronary syndromes.
  • Individuals with for cardiac catheterization.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
718 participants (actual)
Target follow-up
1 Week
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy of the AI-ECG TIMI AI Model

    The primary endpoint is the AI-ECG TIMI model's ability to identify patients with actively occluded (TIMI 0-1) at the time of invasive coronary angiography using only single-standard 12-lead ECGs assessed by accuracy, sensitivity, specificity, positive, negative predictive values and F1 scores.

    Time frame: Index hospitalization (assessed up to 5 days)

Secondary outcomes

  1. Subgroup Performance

    AI-ECG TIMI AI Model's performance across subgroups 1. Demographic 2. Risk factors \& co-morbidities 3. Electrocardiographic 4. Culprit artery territory

    Time frame: Index hospitalization (assessed up to 5 days)

  2. Correlate established definitions of occlusion myocardial infarction (OMI) to myocardial perfusion status

    2\. OMI definitions using routine angiographic and laboratory parameters will be correlated to abnormal myocardial perfusion using correlation coefficients.

    Time frame: Index hospitalization (assessed up to 5 days)

  3. ECG prediction of mechanical reperfusion

    a. Correlation of AI-ECG TIMI model's raw numeric predictions (between 0 and 1) with myocardial perfusion grading post PCI.

    Time frame: Index hospitalization (assessed up to 5 days)

  4. Assessment of expert ECG interpretation blinded to all clinical information

    1. Accuracy, sensitivity, specificity, positive and negative predictive value of expert interpretation of active OMI, reperfused OMI and entirety of OMI 2. Inter-rater variability of expert interpretation of active OMI, reperfused OMI and entirety of OMI.

    Time frame: Index hospitalization (assessed up to 5 days)

  5. STEMI-equivalent ECG patterns

    a. Prevalence of STEMI equivalent ECG patterns and their correlation to TIMI flow grade at angiography.

    Time frame: Index hospitalization (assessed up to 5 days)

  6. Subgroup analysis of NSTEMI-OMI patients

    9\. NSTEMI-OMI stratified according to immediate (\<2h) vs. SoC (\>2h) invasive management, median: i. Peak troponin (maximum rise before fall) ii. Median LVEF at discharge iii. Length of hospital stay iv. Length of cardiac care unit (CCU) or intensive care unit (ICU) stay v. Presence of life-threatening arrhythmias

    Time frame: Index hospitalization (assessed up to 5 days)

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Sep 2026, 21 months.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 21 months is below that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2026 → Sep 2026 and completion May 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2024
First posted
Jul 30, 2024
StartActual
Dec 10, 2024
Primary completionActual
Sep 30, 2026was Mar 2026
CompletionActual
Sep 30, 2026was May 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 18, 2026
Primary completion
Mar 16, 2026→Sep 30, 2026
Nov 18, 2026
Study completion
May 16, 2026→Sep 30, 2026 (actual)
Nov 18, 2026
Enrollment
800 (estimated)→718 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Active, not recruiting→Completed
    Primary completion Mar 16, 2026→Sep 30, 2026
    Study completion May 16, 2026→Sep 30, 2026 (now actual)
    Enrollment 800 (estimated)→718 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06528821
Lead sponsor
Powerful Medical
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Dec 10, 2024
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 18, 2026

Study contacts

Robert Herman, MD, PhD
principal investigator · Powerful Medical
Emanuele Barbato, MD, PhD
study chair · University of Roma La Sapienza
Jozef Bartunek, MD, PhD
study chair · Azorg Hospital, Aalst

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion